Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Squalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.90 |
| ▸ | SLC10A1 | Q14973 | 4/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.48 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Squalamine SCHEMBL29673379 | 1.00 | PTPN1 (0.90) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL29673380 | 0.99 | PTPN1 (0.89) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL22397773 | 0.97 | PTPN1 (0.86) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL14430016 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL22356672 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL21248627 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL20850040 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL12836 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL17359656 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL18838926 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2217 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4352518-A2 | METHODS OF TREATING CANCER WITH CD-40 AGONISTS | Apexigen America, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| CN-117795341-A | Methods of treating cancer using CD-40 agonists | 埃派斯进美国有限公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2022266496-A1 | METHODS OF TREATING KRAS MUTATION SUBTYPES WITH CD40 AGONIST | PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2022256562-A2 | METHODS OF TREATING CANCER WITH CD-40 AGONISTS | PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (US) | 2022-12-08 | — | — | WO | claimed |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2022-03-24 | — | — | US | claimed |
| US-20210332079-A1 | SQUALAMINE SOLID FORMS AND METHODS OF MAKING THE SAME | Enterin, Inc (US) | 2021-10-28 | — | — | US | claimed |
| CN-113286579-A | Systems, devices and methods for using anti-VEGF compounds and treating skin disorders using such compounds | 埃里克·F·伯恩斯坦 | 2021-08-20 | — | — | CN | claimed |
| US-11066438-B2 | Squalamine solid forms and methods of making the same | ENTERIN, INC. (US) | 2021-07-20 | — | — | US | claimed |
| EP-3704132-A1 | NEW SQUALAMINE SOLID FORMS AND METHODS OF MAKING THE SAME | Enterin, Inc. (US) | 2020-09-09 | — | — | EP | claimed |
| US-20190127416-A1 | NEW SQUALAMINE SOLID FORMS AND METHODS OF MAKING THE SAME | ENTERIN, INC. (US) | 2019-05-02 | — | — | US | claimed |
| US-20080226732-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-09-18 | — | — | US | claimed |
| WO-2008078095-A1 | TREATMENT OF MACULAR DEGENERATION | SUMMIT CORPORATION PLC (GB) | 2008-07-03 | — | — | WO | claimed |
| US-20080107741-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-05-08 | — | — | US | claimed |
| US-20080050461-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-02-28 | — | — | US | claimed |
| EP-1800666-A1 | Nanoparticulate compositions of angiogenesis inhibitors | Elan Pharma International Limited (IE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006119211-A2 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS | GENAERA CORPORATION (US) | 2006-11-09 | — | — | WO | claimed |
| EP-1490030-B1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INT LTD (IE) | 2006-10-25 | — | — | EP | claimed |
| EP-1490030-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | Elan Pharma International Limited (IE) | 2004-12-29 | — | — | EP | claimed |
| US-20040033267-A1 | Nanoparticulate compositions of angiogenesis inhibitors | ELAN PHARMA INTERNATIONAL LTD. | 2004-02-19 | — | — | US | claimed |
| WO-2003080027-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |